AIM ImmunoTech Reports Increased Net Loss and Decreased Revenues for Q2 2025

AIM ImmunoTech Inc. reported a net loss of approximately $2.79 million for the three months ended June 30, 2025, compared to a loss of $1.84 million for the same period in 2024, marking a 52% increase in losses. The company's revenues from its Ampligen Cost Recovery Program decreased to $25,000 from $50,000 year-over-year, primarily due to fluctuations in patient participation. For the six months ending June 30, 2025, AIM's net loss was approximately $6.50 million, a decrease from $7.65 million in the prior year, reflecting a 15% reduction in losses. The decrease in losses was attributed to lower general and administrative expenses and reduced research and development costs.

In terms of operational metrics, AIM's research and development expenses for the second quarter of 2025 were approximately $1.17 million, slightly up from $1.15 million in the previous year. General and administrative expenses saw a significant decline, dropping to $1.49 million from $2.59 million, largely due to reduced professional fees and salaries. The company’s total costs and expenses for the quarter were approximately $2.67 million, down from $3.74 million in the same quarter of 2024.

Strategically, AIM has been focusing on its flagship product, Ampligen, which is currently undergoing clinical trials for various applications, including pancreatic cancer and chronic fatigue syndrome. The company has also been exploring potential collaborations and partnerships to enhance its market presence. Notably, AIM executed a reverse stock split of 1-for-100 in June 2025 to comply with NYSE American listing requirements, which had previously been a concern due to the company's stockholders' equity falling below the minimum requirement.

As of June 30, 2025, AIM's cash and cash equivalents totaled approximately $476,000, a decrease from $3.55 million at the end of the previous year. The company has been actively seeking additional funding sources to support its operations and clinical trials, including a recent public offering that raised $8 million in gross proceeds. AIM's management has expressed concerns regarding its ability to continue as a going concern, given its working capital deficit and ongoing operational losses. The company is committed to implementing strategies to regain compliance with NYSE American listing standards and improve its financial position moving forward.